Glucosylceramide Synthase

Glucosylceramide Synthase製品

All (4)
Glucosylceramide Synthase阻害剤 (3)
Glucosylceramide Synthaseモジュレータ(1)
新製品

製品コード	製品名称	製品説明	文献中Selleckの製品使用例
S7852	Eliglustat	Eliglustat (GENZ-112638) inhibits glucosylceramide synthase(GCS),thus reducing the load of glucosylceramide influx into the lysosome.	Eur J Pharmacol, 2024, 966:176366 bioRxiv, 2024, 2024.10.10.617261 Int J Mol Sci, 2023, 24(12)9905
S4433	Eliglustat hemitartrate	Eliglustat hemitartrate (Genz-112638, Eliglustat tartrate) is a potent, specific and orally active inhibitor of glucosylceramide synthase with IC50 of 24 nM.	Biochim Biophys Acta Mol Cell Biol Lipids, 2021, 1866(1):158817 Biol Pharm Bull, 2021, 44(10):1419-1426
E0646	Ibiglustat succinate	Ibiglustat succinate (Venglustat succinate) is a glucosylceramide (GlcCer) synthase inhibitor that blocks the formation of glucosylceramide.	Cell Rep, 2023, 42(12):113431
E0786	N-Desmethyltamoxifen	N-Desmethyltamoxifen, the major metabolite of Tamoxifen in humans and a ten-fold more potent protein kinase C (PKC) inhibitor than Tamoxifen, also is a potent regulator of ceramide metabolism in human AML cells, limiting ceramide glycosylation, hydrolysis, and sphingosine phosphorylation.
S7852	Eliglustat	Eliglustat (GENZ-112638) inhibits glucosylceramide synthase(GCS),thus reducing the load of glucosylceramide influx into the lysosome.	Eur J Pharmacol, 2024, 966:176366 bioRxiv, 2024, 2024.10.10.617261 Int J Mol Sci, 2023, 24(12)9905
S4433	Eliglustat hemitartrate	Eliglustat hemitartrate (Genz-112638, Eliglustat tartrate) is a potent, specific and orally active inhibitor of glucosylceramide synthase with IC50 of 24 nM.	Biochim Biophys Acta Mol Cell Biol Lipids, 2021, 1866(1):158817 Biol Pharm Bull, 2021, 44(10):1419-1426
E0646	Ibiglustat succinate	Ibiglustat succinate (Venglustat succinate) is a glucosylceramide (GlcCer) synthase inhibitor that blocks the formation of glucosylceramide.	Cell Rep, 2023, 42(12):113431
E0786	N-Desmethyltamoxifen	N-Desmethyltamoxifen, the major metabolite of Tamoxifen in humans and a ten-fold more potent protein kinase C (PKC) inhibitor than Tamoxifen, also is a potent regulator of ceramide metabolism in human AML cells, limiting ceramide glycosylation, hydrolysis, and sphingosine phosphorylation.

Glucosylceramide Synthase阻害剤の選択性比較